BPC-157 occupies an unusual position: among the most-discussed compounds in the peptide community and among the least-studied in humans. This review separates what the preclinical literature supports from what marketing extrapolates.
The rodent evidence base is genuinely substantial — over 100 published studies spanning tendon, ligament, muscle, gastrointestinal, and vascular models. Proposed mechanisms center on modulation of VEGF-mediated angiogenesis, upregulation of growth-hormone receptors in fibroblasts, and interaction with the nitric-oxide system.
The human evidence base remains close to empty. No adequately powered randomized human trial has been published. The 2023 FDA compounding classification reflected precisely this absence of human safety data, not a specific harm signal.
For researchers, the honest summary is: mechanistically interesting, preclinically consistent, clinically unproven. Claims of established human efficacy exceed the evidence.
